Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AntiCancer Inc.

Latest From AntiCancer Inc.

US court invalidates one of two Gemzar patents

A US district court has granted a motion filed by Sun Pharma for partial summary judgement in its three-year battle over Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire in May 2013.


Indian court rejects patent linkage in Bayer's sorafenib case - update

The Delhi High Court has indicted Bayer for attempting to use "speculative" litigation in India, in a case concerning Cipla's application to introduce a generic version of Bayer's anticancer Nexavar (sorafenib tosylate).

Infectious Diseases Cancer

Indian court rejects patent linkage in Bayer'ssorafenib case

The High Court in Delhi, India has indicted Bayer for "speculative" litigation in a case concerning Cipla's marketing application for a generic version of the anticancer sorafenib tosylate.


Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial

Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as second-line therapy.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Contract Research, Toxicology Testing-CRO
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery